Swiss National Bank Has $671.75 Million Stock Position in Abbott Laboratories $ABT

Swiss National Bank lowered its stake in shares of Abbott Laboratories (NYSE:ABT) by 4.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 5,015,280 shares of the healthcare product maker’s stock after selling 234,600 shares during the quarter. Swiss National Bank owned about 0.29% of Abbott Laboratories worth $671,747,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Carr Financial Group Corp raised its position in shares of Abbott Laboratories by 2.0% during the third quarter. Carr Financial Group Corp now owns 3,880 shares of the healthcare product maker’s stock valued at $520,000 after buying an additional 76 shares during the last quarter. Tortoise Investment Management LLC grew its position in Abbott Laboratories by 10.7% during the second quarter. Tortoise Investment Management LLC now owns 795 shares of the healthcare product maker’s stock worth $108,000 after buying an additional 77 shares in the last quarter. Gemmer Asset Management LLC increased its stake in Abbott Laboratories by 2.9% during the third quarter. Gemmer Asset Management LLC now owns 2,750 shares of the healthcare product maker’s stock valued at $368,000 after acquiring an additional 78 shares during the period. Global Financial Private Client LLC raised its holdings in Abbott Laboratories by 3.3% in the 3rd quarter. Global Financial Private Client LLC now owns 2,469 shares of the healthcare product maker’s stock valued at $331,000 after acquiring an additional 79 shares in the last quarter. Finally, Citizens & Northern Corp lifted its position in shares of Abbott Laboratories by 0.4% in the 3rd quarter. Citizens & Northern Corp now owns 21,875 shares of the healthcare product maker’s stock worth $2,930,000 after acquiring an additional 79 shares during the period. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories Stock Performance

Shares of NYSE:ABT opened at $109.74 on Monday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. The business’s fifty day moving average price is $116.09 and its two-hundred day moving average price is $124.57. Abbott Laboratories has a fifty-two week low of $105.27 and a fifty-two week high of $139.15. The stock has a market capitalization of $190.69 billion, a price-to-earnings ratio of 29.50, a price-to-earnings-growth ratio of 1.74 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The company had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. During the same period last year, the business earned $1.34 earnings per share. The business’s revenue was up 4.4% on a year-over-year basis. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a $0.63 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. Abbott Laboratories’s payout ratio is 67.74%.

Insider Activity

In other news, EVP Mary K. Moreland sold 613 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $70,850.54. Following the completion of the sale, the executive vice president owned 104,291 shares of the company’s stock, valued at approximately $12,053,953.78. This trade represents a 0.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Elizabeth C. Cushman sold 263 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $30,397.54. Following the completion of the transaction, the executive vice president directly owned 38,573 shares in the company, valued at $4,458,267.34. The trade was a 0.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 3,055 shares of company stock valued at $353,097. Corporate insiders own 0.46% of the company’s stock.

Wall Street Analysts Forecast Growth

ABT has been the topic of a number of research reports. BTIG Research lowered their price objective on Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating on the stock in a research report on Tuesday, February 17th. Oppenheimer decreased their price target on shares of Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Royal Bank Of Canada lowered their price target on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Argus reduced their price objective on shares of Abbott Laboratories from $150.00 to $140.00 in a report on Tuesday, January 27th. Finally, Raymond James Financial decreased their target price on shares of Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, Abbott Laboratories has an average rating of “Moderate Buy” and a consensus price target of $137.05.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.